Kura Oncology Stock Price To Sales
| KURA Stock | USD 7.27 0.07 0.95% |
Kura Oncology fundamentals help investors to digest information that contributes to Kura Oncology's financial success or failures. It also enables traders to predict the movement of Kura Stock. The fundamental analysis module provides a way to measure Kura Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kura Oncology stock.
Kura |
Kura Oncology Company Price To Sales Analysis
Kura Oncology's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Kura Oncology Price To Sales | 10.90 X |
Most of Kura Oncology's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kura Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Kura Oncology has a Price To Sales of 10.8956 times. This is 49.09% lower than that of the Biotechnology sector and 88.93% lower than that of the Health Care industry. The price to sales for all United States stocks is 4.59% higher than that of the company.
Kura Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kura Oncology's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics of similar companies.Kura Oncology is currently under evaluation in price to sales category among its peers.
Kura Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (0.42) % | ||||
| Current Valuation | (123.71 M) | ||||
| Shares Outstanding | 80.75 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 98.86 % | ||||
| Number Of Shares Shorted | 9.25 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 1.42 X | ||||
| Price To Sales | 10.90 X | ||||
| Revenue | 53.88 M | ||||
| Gross Profit | (101.46 M) | ||||
| EBITDA | (169.5 M) | ||||
| Net Income | (173.98 M) | ||||
| Cash And Equivalents | 450.26 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 16.59 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.73 X | ||||
| Book Value Per Share | 5.29 X | ||||
| Cash Flow From Operations | 134.32 M | ||||
| Short Ratio | 5.40 X | ||||
| Earnings Per Share | (2.02) X | ||||
| Target Price | 26.69 | ||||
| Number Of Employees | 192 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 587.09 M | ||||
| Total Asset | 760.16 M | ||||
| Retained Earnings | (895.42 M) | ||||
| Working Capital | 666.12 M | ||||
| Current Asset | 86.87 M | ||||
| Current Liabilities | 5.05 M | ||||
| Net Asset | 760.16 M |
About Kura Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Kura Oncology Piotroski F Score and Kura Oncology Altman Z Score analysis. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.